Allograft Cellular Bone Matrix in Extreme Lateral Interbody Fusion: Preliminary Radiographic and Clinical Outcomes
Introduction. Extreme lateral interbody fusion (XLIF) is a minimally disruptive alternative for anterior lumbar interbody fusion. Recently, synthetic and allograft materials have been increasingly used to eliminate donor-site pain and complications secondary to autogenous bone graft harvesting. The...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/263637 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560389122949120 |
|---|---|
| author | Antoine G. Tohmeh Blake Watson Mirna Tohmeh Xavier J. Zielinski |
| author_facet | Antoine G. Tohmeh Blake Watson Mirna Tohmeh Xavier J. Zielinski |
| author_sort | Antoine G. Tohmeh |
| collection | DOAJ |
| description | Introduction. Extreme lateral interbody fusion (XLIF) is a minimally disruptive alternative for anterior lumbar interbody fusion. Recently, synthetic and allograft materials have been increasingly used to eliminate donor-site pain and complications secondary to autogenous bone graft harvesting. The clinical use of allograft cellular bone graft has potential advantages over autograft by eliminating the need to harvest autograft while mimicking autograft's biologic function. The objective of this study was to examine 12-month radiographic and clinical outcomes in patients who underwent XLIF with Osteocel Plus, one such allograft cellular bone matrix. Methods. Forty (40) patients were treated at 61 levels with XLIF and Osteocel Plus and included in the analysis. Results. No complications were observed. From preoperative to 12-month postoperative followup, ODI improved 41%, LBP improved 55%, leg pain improved 43.3%, and QOL (SF-36) improved 56%. At 12 months, 92% reported being “very” or “somewhat” satisfied with their outcome and 86% being either “very” or “somewhat likely” to choose to undergo the procedure again. Complete fusion was observed in 90.2% (55/61) of XLIF levels. Conclusions. Complete interbody fusion with Osteocel Plus was shown in 90.2% of XLIF levels, with the remaining 9.8% being partially consolidated and progressing towards fusion at 12 months. |
| format | Article |
| id | doaj-art-6b0beb45266242bc979e127b01c0a9d2 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-6b0beb45266242bc979e127b01c0a9d22025-02-03T01:27:42ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/263637263637Allograft Cellular Bone Matrix in Extreme Lateral Interbody Fusion: Preliminary Radiographic and Clinical OutcomesAntoine G. Tohmeh0Blake Watson1Mirna Tohmeh2Xavier J. Zielinski3Northwest Orthopaedic Specialists, Spokane, WA 99208, USAInland Imaging, Spokane, WA 99204, USASpine Research Institute of Spokane, PLLC, USAInland Imaging, Spokane, WA 99204, USAIntroduction. Extreme lateral interbody fusion (XLIF) is a minimally disruptive alternative for anterior lumbar interbody fusion. Recently, synthetic and allograft materials have been increasingly used to eliminate donor-site pain and complications secondary to autogenous bone graft harvesting. The clinical use of allograft cellular bone graft has potential advantages over autograft by eliminating the need to harvest autograft while mimicking autograft's biologic function. The objective of this study was to examine 12-month radiographic and clinical outcomes in patients who underwent XLIF with Osteocel Plus, one such allograft cellular bone matrix. Methods. Forty (40) patients were treated at 61 levels with XLIF and Osteocel Plus and included in the analysis. Results. No complications were observed. From preoperative to 12-month postoperative followup, ODI improved 41%, LBP improved 55%, leg pain improved 43.3%, and QOL (SF-36) improved 56%. At 12 months, 92% reported being “very” or “somewhat” satisfied with their outcome and 86% being either “very” or “somewhat likely” to choose to undergo the procedure again. Complete fusion was observed in 90.2% (55/61) of XLIF levels. Conclusions. Complete interbody fusion with Osteocel Plus was shown in 90.2% of XLIF levels, with the remaining 9.8% being partially consolidated and progressing towards fusion at 12 months.http://dx.doi.org/10.1100/2012/263637 |
| spellingShingle | Antoine G. Tohmeh Blake Watson Mirna Tohmeh Xavier J. Zielinski Allograft Cellular Bone Matrix in Extreme Lateral Interbody Fusion: Preliminary Radiographic and Clinical Outcomes The Scientific World Journal |
| title | Allograft Cellular Bone Matrix in Extreme Lateral Interbody Fusion: Preliminary Radiographic and Clinical Outcomes |
| title_full | Allograft Cellular Bone Matrix in Extreme Lateral Interbody Fusion: Preliminary Radiographic and Clinical Outcomes |
| title_fullStr | Allograft Cellular Bone Matrix in Extreme Lateral Interbody Fusion: Preliminary Radiographic and Clinical Outcomes |
| title_full_unstemmed | Allograft Cellular Bone Matrix in Extreme Lateral Interbody Fusion: Preliminary Radiographic and Clinical Outcomes |
| title_short | Allograft Cellular Bone Matrix in Extreme Lateral Interbody Fusion: Preliminary Radiographic and Clinical Outcomes |
| title_sort | allograft cellular bone matrix in extreme lateral interbody fusion preliminary radiographic and clinical outcomes |
| url | http://dx.doi.org/10.1100/2012/263637 |
| work_keys_str_mv | AT antoinegtohmeh allograftcellularbonematrixinextremelateralinterbodyfusionpreliminaryradiographicandclinicaloutcomes AT blakewatson allograftcellularbonematrixinextremelateralinterbodyfusionpreliminaryradiographicandclinicaloutcomes AT mirnatohmeh allograftcellularbonematrixinextremelateralinterbodyfusionpreliminaryradiographicandclinicaloutcomes AT xavierjzielinski allograftcellularbonematrixinextremelateralinterbodyfusionpreliminaryradiographicandclinicaloutcomes |